SynAct Pharma AB (OSTO:SYNACT) Debt-to-Asset : 0.00 (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is SynAct Pharma AB Debt-to-Asset?

SynAct Pharma AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.47 Mil. SynAct Pharma AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.02 Mil. SynAct Pharma AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was kr213.35 Mil. SynAct Pharma AB's debt to asset for the quarter that ended in Mar. 2024 was 0.00.

SynAct Pharma AB Debt-to-Asset Historical Data

The historical data trend for SynAct Pharma AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SynAct Pharma AB Debt-to-Asset Chart

SynAct Pharma AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.08

0.01

SynAct Pharma AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial															0.01	-	-	-	-

Competitive Comparison of SynAct Pharma AB's Debt-to-Asset

For the Biotechnology subindustry, SynAct Pharma AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SynAct Pharma AB's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SynAct Pharma AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where SynAct Pharma AB's Debt-to-Asset falls into.

SynAct Pharma AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

SynAct Pharma AB's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.579	+	0.058)	/	228.018
	=	0.00

SynAct Pharma AB's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.474	+	0.024)	/	213.354
	=	0.00

SynAct Pharma AB (OSTO:SYNACT) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

SynAct Pharma AB Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of SynAct Pharma AB's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

SynAct Pharma AB (OSTO:SYNACT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SynAct Pharma AB (OSTO:SYNACT) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

8F8:Germany

Address

Sheelevagen 2, Lund, SWE, 223 81

Website

https://www.synactpharma.se

SynAct Pharma AB is a clinical-stage biotech company focused on resolving inflammation through selective activation of the melanocortin system. The company has a platform technology based on a new class of drug candidates that target acute exacerbations in chronic inflammatory diseases with the primary aim of stimulating natural healing mechanisms. AP1189, the company's lead drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.

SynAct Pharma AB (OSTO:SYNACT) Headlines

No Headlines